BACKGROUND: A relapse prevention program called the Information Technology Aided Relapse Prevention Programme in Schizophrenia (ITAREPS) has been developed and is reported to be highly effective. However the effectiveness was influenced by user adherence to the protocol of the program, the exact effectiveness and the role of the ITAREPS have been partially uncertain. OBJECTIVE: The purpose of this study is to evaluate the effectiveness of the ITAREPS excluding the effect of user adherence to the protocol of the program. METHOD: We attempted to perform a randomized controlled trial by the devised method with visiting nurse service. Outpatients with schizophrenia were randomized to the ITAREPS (n=22) or control group (n=23) and were observed for 12 months. RESULTS: The risk of rehospitalization was reduced in the ITAREPS group (2 [9.1%]) compared with the control group (8 [34.8%]) (hazard ratio=0.21, 95% CI 0.04-0.99, p=0.049; number needed to treat (NNT)=4, 95% CI 2.1-35.5). The mean number of inpatient days was significantly lower in the ITAREPS group (18.5 days) compared with the control group (88.8 days) (p=0.036). The ratio of the number of rehospitalizations to that of relapses was significantly lower (p=0.035) and the mean change in total BPRS scores at relapse from baseline was significantly less in the ITAREPS group (p=0.019). CONCLUSIONS: The relapse prevention effectiveness of the ITAREPS was high, and we confirmed that the ITAREPS, i.e., detecting signs of relapse and increasing medication during the warning state, is an effective intervention during the early stages of relapse.
RCT Entities:
BACKGROUND: A relapse prevention program called the Information Technology Aided Relapse Prevention Programme in Schizophrenia (ITAREPS) has been developed and is reported to be highly effective. However the effectiveness was influenced by user adherence to the protocol of the program, the exact effectiveness and the role of the ITAREPS have been partially uncertain. OBJECTIVE: The purpose of this study is to evaluate the effectiveness of the ITAREPS excluding the effect of user adherence to the protocol of the program. METHOD: We attempted to perform a randomized controlled trial by the devised method with visiting nurse service. Outpatients with schizophrenia were randomized to the ITAREPS (n=22) or control group (n=23) and were observed for 12 months. RESULTS: The risk of rehospitalization was reduced in the ITAREPS group (2 [9.1%]) compared with the control group (8 [34.8%]) (hazard ratio=0.21, 95% CI 0.04-0.99, p=0.049; number needed to treat (NNT)=4, 95% CI 2.1-35.5). The mean number of inpatient days was significantly lower in the ITAREPS group (18.5 days) compared with the control group (88.8 days) (p=0.036). The ratio of the number of rehospitalizations to that of relapses was significantly lower (p=0.035) and the mean change in total BPRS scores at relapse from baseline was significantly less in the ITAREPS group (p=0.019). CONCLUSIONS: The relapse prevention effectiveness of the ITAREPS was high, and we confirmed that the ITAREPS, i.e., detecting signs of relapse and increasing medication during the warning state, is an effective intervention during the early stages of relapse.
Authors: Cathaleene Macias; Trishan Panch; Yale M Hicks; Jason S Scolnick; David Lyle Weene; Dost Öngür; Bruce M Cohen Journal: Psychiatr Q Date: 2015-12
Authors: Andrew I Gumley; Simon Bradstreet; John Ainsworth; Stephanie Allan; Mario Alvarez-Jimenez; Maximillian Birchwood; Andrew Briggs; Sandra Bucci; Sue Cotton; Lidia Engel; Paul French; Reeva Lederman; Shôn Lewis; Matthew Machin; Graeme MacLennan; Hamish McLeod; Nicola McMeekin; Cathy Mihalopoulos; Emma Morton; John Norrie; Frank Reilly; Matthias Schwannauer; Swaran P Singh; Suresh Sundram; Andrew Thompson; Chris Williams; Alison Yung; Lorna Aucott; John Farhall; John Gleeson Journal: Health Technol Assess Date: 2022-05 Impact factor: 4.106
Authors: Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis Journal: Schizophr Bull Date: 2015-03-05 Impact factor: 9.306
Authors: R Sfetcu; S Musat; P Haaramo; M Ciutan; G Scintee; C Vladescu; K Wahlbeck; H Katschnig Journal: BMC Psychiatry Date: 2017-06-24 Impact factor: 3.630
Authors: Glenn J Treisman; Geetha Jayaram; Russell L Margolis; Godfrey D Pearlson; Chester W Schmidt; Gary L Mihelish; Adrienne Kennedy; Alexandra Howson; Maziar Rasulnia; Iwona E Misiuta Journal: J Nerv Ment Dis Date: 2016-08 Impact factor: 2.254